Featured Research

from universities, journals, and other organizations

High-dose Radiation Reduces Risk Of Prostate Cancer Recurrence

Date:
September 14, 2005
Source:
JAMA and Archives Journals
Summary:
Men with localized prostate cancer who received high-dose external radiation therapy were less likely to have cancer recurrence than men who received conventional-dose radiation therapy, according to an article in the September 14 issue of JAMA.

Men with localized prostate cancer who received high-dose externalradiation therapy were less likely to have cancer recurrence than menwho received conventional-dose radiation therapy, according to anarticle in the September 14 issue of JAMA.

The majority of cases of prostate cancer now diagnosed in the UnitedStates are detected while the disease is still clinically localized,according to background information in the article. External beamradiation is one of the options used to treat more than 26,000 U.S. menannually. Failure after treatment with conventional radiation therapyis common, with a resultant increase in prostate-specific antigen (PSA)levels, secondary treatment, and, ultimately, clinical recurrence.Increasing the delivered radiation dose may increase the probability oflocal tumor control but carries a risk of greater adverse effectsunless the volume of normal tissue treated along with the tumor can bereduced.

In the 1990s a number of computed tomography-based techniquesbecame available to deliver radiation more accurately and thus allowthe delivery of higher doses. These techniques are together known as"3-dimensional conformal therapy" and include the use of conformalphoton beams, intensity-modulated photon beams, and proton beams.

Anthony L. Zietman, M.D., of Massachusetts General Hospitaland Harvard Medical School, Boston, and colleagues conducted a study todetermine whether tumor control could be improved in patients withprostate cancer, including those with low-risk disease, by the use ofhigher radiation doses. The study included 393 patients with stage T1bthrough T2b prostate cancer and prostate-specific antigen (PSA) levelsless than 15 ng/mL, randomized between January 1996 and December 1999.The median (middle) value for PSA levels was 6.3 ng/mL, and the medianfollow-up time was 5.5 years. Patients received either external beamradiation to a total dose of either 70.2 Gy (radiation dose unit;conventional dose) or 79.2 Gy (high dose). This was delivered using acombination of conformal photon and proton beams.

The researchers found that the proportions of men free frombiochemical failure (increasing PSA level) at 5 years were 61.4 percentfor conventional-dose and 80.4 percent for high-dose therapy, a 49percent reduction in the risk of failure. The advantage to high-dosetherapy was observed in both the low-risk and the higher-risk subgroups(risk reduction, 51 percent and 44 percent, respectively). There hasbeen no significant difference in overall survival rates between thetreatment groups. Only 1 percent of patients receivingconventional-dose and 2 percent receiving high-dose radiationexperienced acute urinary or rectal problems of Radiation TherapyOncology Group (RTOG) grade 3 or greater. So far, only 2 percent and 1percent, respectively, have experienced late problems having RTOG grade3 or greater.

"This randomized trial shows that when men with clinicallylocalized prostate cancer are treated with high-dose rather thanconventional-dose external radiation therapy, they are more likely tobe free from an increasing PSA level 5 years later and less likely tohave locally persistent disease," the authors conclude.

###

(JAMA. 2005; 294:1233 - 1239. Available pre-embargo to the media at www.jamamedia.org.)

Editor's Note: This trial was supported by a grant from the National Cancer Institute.

Editorial: Radiation Dose Escalation as Treatment for Clinically Localized Prostate Cancer - Is More Really Better?

In an accompanying editorial, Theodore L. DeWeese, M.D., andDanny Y. Song, M.D., of Johns Hopkins University School of Medicine,Baltimore, comment on the study and on radiation dose level forprostate cancer.

"Based on the study by Zietman et al, it is possible to nowstate with more certainty that higher radiation doses can be safelydelivered to men with clinically localized prostate cancer and thatthis increased dose is associated with improved biochemical control ofdisease. However, whether this increase in PSA control will necessarilytranslate into improvement in clinically meaningful end points such aslonger survival is not yet known. As such, this study has not answeredthe important question of whether patients should accept the modest butreal incremental risk of higher radiation doses for the uncertainultimate benefit derived."

"Several other questions also remain unanswered: (1) Wouldhigher radiation doses beyond 79 Gy provide even greater benefit? (2)What is the optimal radiation method of dose escalation? and (3) Giventhat the addition of androgen suppression to radiotherapy has recentlybeen shown to improve survival in some patients, is dose escalationeven the best way to improve radiotherapeutic outcomes in this disease?Nevertheless, these randomized trial data support the use of higherradiation doses in men with lower-risk prostate cancer, and thesefindings will serve as an important foundation for future work," theywrite.

(JAMA. 2005; 294:1274 - 1276. Available pre-embargo to the media at www.jamamedia.org.)


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Cite This Page:

JAMA and Archives Journals. "High-dose Radiation Reduces Risk Of Prostate Cancer Recurrence." ScienceDaily. ScienceDaily, 14 September 2005. <www.sciencedaily.com/releases/2005/09/050914105900.htm>.
JAMA and Archives Journals. (2005, September 14). High-dose Radiation Reduces Risk Of Prostate Cancer Recurrence. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2005/09/050914105900.htm
JAMA and Archives Journals. "High-dose Radiation Reduces Risk Of Prostate Cancer Recurrence." ScienceDaily. www.sciencedaily.com/releases/2005/09/050914105900.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Artificial Sweetener Could Promote Diabetes

Artificial Sweetener Could Promote Diabetes

Newsy (Sep. 17, 2014) Doctors once thought artificial sweeteners lacked the health risks of sugar, but a new study says they can impact blood sugar levels the same way. Video provided by Newsy
Powered by NewsLook.com
Ebola Vaccine Trial Gets Underway at Oxford University

Ebola Vaccine Trial Gets Underway at Oxford University

AFP (Sep. 17, 2014) A healthy British volunteer is to become the first person to receive a new vaccine for the Ebola virus after US President Barack Obama called for action against the epidemic and warned it was "spiralling out of control." Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Obesity Rates Steady Even As Americans' Waistlines Expand

Obesity Rates Steady Even As Americans' Waistlines Expand

Newsy (Sep. 17, 2014) Researchers are puzzled as to why obesity rates remain relatively stable as average waistlines continue to expand. Video provided by Newsy
Powered by NewsLook.com
President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins